Clal Biotechnology reported ILS5.15M in Operating Expenses for its fiscal quarter ending in December of 2022.





Operating Expenses Change Date
aTyr Pharma USD 26.94M 6.63M Sep/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
RedHill Biopharma USD 5.51M 1.08M Jun/2024